Patient characteristics, values of health status and composite indices at baseline and for reliability and responsiveness assessment
| Patient characteristics | Baseline (n=1548) | Reliability, first visit (n=578) | Reliability, second visit (n=578) | Responsiveness first visit (n=246)* | Responsiveness second visit* (n=246) |
| Age (years) | 42.0 (13.4) | 45.3 (13.7) | 37.2 (12.2) | ||
| Male, n (%) | 1005 (64.9) | 372 (64.4) | 152 (61.8) | ||
| Symptom duration (years) | 14.5 (11.4) | 16.6 (11.9) | 10.9 (9.5) | ||
| Extraspinal manifestation, current, n (%) | |||||
| Arthritis | 301 (19.4) | 99 (17.1) | 43 (17.4) | ||
| Dactylitis | 50 (3.2) | 9 (1.6) | 11 (4.5) | ||
| Enthesitis | 261 (16.9) | 80 (13.8) | 44 (17.9) | ||
| Extra-articular manifestation, current, n (%) | |||||
| Uveitis | 53 (3.4) | 17 (2.9) | 5 (2.0) | ||
| IBD | 65 (4.2) | 32 (5.5) | 7 (2.8) | ||
| Skin psoriasis | 110 (7.1) | 51 (8.8) | 3 (1.2) | ||
| HLA-B27 positive, n (%) | 994 (77.0) | 350 (73.9) | 107 (71.9) | ||
| CRP (mg/L), sample n=1353 | 9.8 (16.01) | 6.8 (10.2) | – | 16.7 (22.6) | 6.7 (11.4) |
| Elevated CRP (≥0.5 mg/L), n (%) | 765 (49.4) | 256 (44.3) | – | 100 (64.5) | 48 (31.0) |
| Current NSAID treatment | 994 (64.2) | 364 (63.0) | 119 (76.8) | ||
| Current csDMARD treatment | 402 (26.2) | 166 (28.7) | 35 (22.6) | ||
| Current TNFi treatment | 591 (38.2) | 240 (41.5) | 23 (14.8) | ||
| ASAS HI (0–17) | 6.7 (4.3) | 6.2 (4.2) | 6.0 (4.2) | 8.2 (3.9) | 5.7 (4.0) |
| ASDAS | 2.5 (1.2) | 2.6 (1.1) | – | 3.3 (1.0) | 1.9 (1.0) |
| BASDAI | 4.1 (2.5) | 3.7 (2.3) | 3.4 (2.1) | 5.4 (2.1) | 3.0 (2.1) |
| BASFI | 3.3 (2.8) | 3.1 (2.7) | 3.1 (2.7) | 4.1 (2.7) | 2.4 (2.3) |
| Pain, NRS 0–10 | 4.4 (2.9) | 3.8 (2.6) | 3.6 (2.4) | 6.1 (2.4) | 3.0 (2.1) |
| Physician global, NRS 0–10 | 3.7 (2.3) | 3.1 (2.0) | – | 5.6 (2.1) | 2.4 (1.7) |
| Patient global, NRS 0–10 | 4.5 (2.8) | 3.8 (2.5) | 3.6 (2.3) | 5.9 (2.4) | 2.3 (1.7) |
| Well-being last week | 4.4 (2.8) | 3.8 (2.6) | 3.5 (2.3) | 5.8 (2.5) | 2.4 (2.0) |
| PASS yes | 801 (51.7) | 368 (63.7) | 401 (69.4) | 45 (29.0) | 130 (83.9) |
| HADS anxiety | 17.6 (3.9) | 18.0 (3.8) | 18.3 (3.8) | 16.6 (3.9) | 18.5 (3.6) |
| HADS depression | 15.3 (3.5) | 15.9 (3.5) | 15.7 (3.5) | 14.4 (3.4) | 16.0 (3.4) |
| EQ-5D VAS (0–100 mm) | 61.6 (22.7) | 63.9 (22.6) | 65.3 (22.6) | 57.5 (20.2) | 67.3 (22.1) |
| EQ-5D (pooled)† | 0.67 (0.2) | 0.7 (0.2) | 0.7 (0.2) | 0.7 (0.2) | 0.7 (0.2) |
| SF-36 PSC | 38.9 (10.5) | 40. 4 (10.2) | 40.6 (10.2) | 34.4 (9.3) | 41.3 (9.5) |
| SF-36 MSC | 47.0 (11.5) | 48.6 (11.2) | 48.5 (11.2) | 43.5 (10.9) | 48.7 (11.0) |
| WPAI, presenteeism | 29.2 (26.0) | 23.4 (23.4) | 21.9 (21.1) | 39.3 (27.4) | 23.6 (21.9) |
| WPAI, absenteeism‡ | 16.0 (32.3) | 11.68±27.5 | 10.5 (27.3) | 31.0±42.7 | 10.9±27.3 |
Values are presented as mean (SD) or absolute number (%). Percentages are % of available data. Fewer than 5% of the data were missing, except for HLA-B27 with 16.6%, CRP with 8.7% and EQ-5D with 9.7% at baseline visit and ASDAS (in responsiveness arm) with 7.3%. CRP and physician global were not measured in the reliability arm at the second visit.
*Only data analysed from those patients who stated that they improved during the time interval.
†The phrase EQ pooled means that EQ-5D-5L analysis was based on the five-level value set for UK except for France, Germany, Netherlands, Spain, Thailand and USA for which the country-specific value set was used .
‡Calculated for employed patients (n=961); see online supplementary file 4.
ASAS HI, ASAS Health Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; EQ-5D, Euro Quality of Life 5 Dimensions; HADS, Hospital Anxiety Depression Scale; HLA, human leucocyte antigen; IBD, inflammatory bowel disease; MSC, mental component summary score; NRS, numerical rating scale; NSAID, non-steroidal antirheumatic drug; PASS, Patient Acceptable Symptom State; PSC, physical component summary score; SF-36, Short Form 36; TNFi, tumour necrosis factor inhibitor; VAS, Visual Analogue Scale; WPAI, Work Productivity and Impairment Scale.